Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000175108 | SCV000226538 | uncertain significance | not provided | 2015-05-11 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001079265 | SCV001089948 | likely benign | Ellis-van Creveld syndrome; Curry-Hall syndrome | 2025-01-08 | criteria provided, single submitter | clinical testing | |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV003398888 | SCV004122715 | uncertain significance | not specified | 2023-10-10 | criteria provided, single submitter | clinical testing | Variant summary: EVC c.2305-6C>T alters a nucleotide located close to a canonical splice site and therefore could affect mRNA splicing, leading to a significantly altered protein sequence. Consensus agreement among computation tools predict no significant impact on normal splicing. However, these predictions have yet to be confirmed by functional studies. The variant allele was found at a frequency of 4.8e-05 in 250726 control chromosomes (gnomAD). To our knowledge, no occurrence of c.2305-6C>T in individuals affected with Ellis-van Creveld syndrome and no experimental evidence demonstrating its impact on protein function have been reported. Two submitters have cited clinical-significance assessments for this variant to ClinVar after 2014. One submitter classified the variant as likely benign, and one submitter classified the variant as uncertain significance. Based on the evidence outlined above, the variant was classified as uncertain significance. |